#
#
#
#
##
##
|Contents|||||~Pa e|
|---|---|---|---|---|---|
|Reference|and Administrative|||Details ofthe Charity|3 —4|
|Trustee's|Report||||5 —22|
|Statement|ofTrustee's||responsibilities||23|
|Independent
auditor's||report|||24-27|
|Foreword|||||28|
|Statement|ofFinancial|Activities|||29|
|Balance Sheet|||||30|
|Statement|ofCashflow||||31|
|Statement|ofAccounting||Policies||32 - 36|
|Notes to the Financial||Statements|||37-45|
##
##
##
##
#
##
##
##
##
##
##
##
##
##
##
##
##
|mbers", dunn
-'.the:|eno|d.,A
ril'..'2022':;to:Janua, ',2023:.||
|---|---|---|---|
|Ngozi Lyn Cote|-|Chair ofCommittee
/ Non-Executive|Director|
|Hayley, Wardle||Executive Director ofFinance from 1 April 2021||
|Melanic Johnson||Executive Director of Nursing,
Midwifery
and AHPs||
|Anita Hagon||Council ofGovernor Representative|from September|
|||2022||
|Karen White||South Tyneside
Public Constituency|to June 2022|
|Joyce Welsh||South Tyneside
Public Constituency|from 1 October|
|||2021 until August 2022||
|Roy McLachlan||Non-Executive
Director - from 15August 2022||
|Angela Thompson||Council ofGovernor
Representative|from September|
|||2022 to August 2023||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||||||Total|||Total|
|---|---|---|---|---|---|---|---|---|---|---|---|
|||Notes|Unrestricted|'|Restricted|Endowment||2023|||2022|
||||Funds||Funds||Funds|Funds|.||Funds|
||||f000|'|f000||OOOO|ROOO|||OOOO|
|Income from:-
Donations
&Legacies
Grants
,
Charitable
Activities
Other Trading Activities
Investments
Total Income
=-
'
Expenditure
on|2,734
0
2,737
2.4
3
9.3
60
5
165
0
0
0:60
0
80
0
3
173
—„:
3,044
,,8
3
3;055
I||||||||||2,349
70
92
81
2,:598|
|Raising Funds|||(28)||(1)||o|(27)|||(59)|
|Charitable
Activities|||(1,058):||(13)||0|(1,069)||(1,193)||
|'Total Expenditure||||||||||||
|Net (Loss)IGain on investments||9.1|(234)||.(5)||0|(239)||'|87|
|,. Net Incomer( Expenditure)|.|!|1,728||(11),||3|1,720|||1,433|
|Transfer between funds|||||0|.|(3)|0|||:0|
|||||||||'||||
|Net movement
in funds|||1,731||(11)||0|1,720|||1,433|
|Reconciliation
ofFunds||||||||||||
|Total funds brought
forward|||8,219||17,7||159|8,555|||7,122|
|Total funds carried forward|||9,9iO||||159|10,275||.|8,555|
##
|||||||||Total||Total|
|---|---|---|---|---|---|---|---|---|---|---|
||Notes|Unrestricted|Restricted||Endowment|||2023||2022|
|||Funds|Funds|||Funds||Funds||Funds|
|||f000|f000|||f000||f000||f000|
|Non current assets|||||||||||
|Investments|9.1,92|3,334|147|||0||3,481||3,790|
|Total non-current
assets||3,334|147|||0||3,481.||3,790|
|Current assets|||||||||||
|Trade and other receivables|10||0|||0||44||35|
|Cash and cash equivalents||6,838|38|||159||7,035||5,373|
|Total current assets||6,882|38|'||159||7,079||5,408|
|Current liabilities|||||||||||
|Trade and other payables||(266)|(19)|||0||'(285)||(643)|
|Net current assets||6,616|19|||159||6,794||4,765|
|Total net assets||9,950|166||.|159||10,275|.|8,555|
|Retained funds ofthe Charity|||||||||||
|Endowment
Funds|13.1|0|0|||159||159||159|
|Restricted Income Funds|13.3|0|166|||0||166||177|
|.Unrestricted
Income Funds|13.5|9,950|0|||0||9,950||8,219|
|Total retained funds ofthe Charity||9,950|166|||159|.|10,275||8,555|
##
|||Year Ended|Year Ended|
|---|---|---|---|
|||31March 23|31March 22|
|||R'000s'|'K'000s|
|Net income and expenditure
for the reporting|period|1,720|1,433,|
|(Increase) in current debtors||(9)|(8)|
|' Investment
income received||(173)|(81)|
|Net Loss on investments
revaluation||239|(87)|
|(Decrease) / Increase
in current creditors||(358)|494|
|Net.cash inflow/(outflow)
from operating|activities|- 1,419|. - 1,751|
|Disposal at sale proceeds values||1,274|219|
|Acquisitions
at cost||(1,204)|(209)|
|Inve'stment
income received||173|81|
|Net cash inflow/(ouffiow)
from investment|activities||91|
|Net cash inflowl(oufflow)
cash and cash|equivalents|1,552|1,&42|
|Cash and cash equivalents
at beginning|ofthe period|5,373|3,531|
|Cash and cash equivalents
at end ofthe|period|7035|5,373|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||,|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|2|||||||||||Total|||Total|
|||||||Unrestricted|Restricted||Endowment||2023|||2022|
|||||||Funds||Funds|Funds||Funds|||Funds|
|||||||f000||OOOO|f000||f000||'|OOOO|
|2.1,-,Donations|||||||||||||||
||Donations from individuals|||||147||3'|0||150|||214|
||Donations from charities|||'||9||0|0||9|||4|
||Corporate donations||CHolCE|||2,500||0|0||2,500|||2,000|
||Corporate donations||other|||10||0|0||10|||16|
||Non corporate donations|||||.11
2,677,|0
' ""
3'||0
"'
0||11
2,680|||12
2,246|
||Analysis ofdonations||from individuals-||||||||||||
|||||||f000|received||:Number|of|deposits|.|||
|||||||2023||2022|2023||2022||||
||Indivi'duels
giving
Individuals
gMng|&f1k
& F100||||Sg
75.||78
78|26
286|-|'
26
249||||
||Fundraising - voluntary (not||||via STSFT)|9||50|16||14||||
||Other
Totals|||||. 7. . ..
150-,||. 8
214.|183
510,|.|200.,
489,.||||
||||||||||||Total|||Total|
|||||||Unrestricted|Restricted||Endowment||2023|||2022|
|||||||Funds||Funds|Funds||Funds|||Funds|
|||||||OOOO,||OOOO|OOOO||f000|||f000|
|2.2|Legacies||||||||||||||
||Perioperatlve
+Critical Care|||||36||0|0||36|||0|
||Rehab and Elderly Medicine|||||3||0'|0||3|||0|
||Medical Specialties|||||6||0|0||6|||100|
||Ophthalmology|||||11||0|0||11|||3|
||General Pur'p'oses|||||||0|0||1
'|||0|
|||||||57||0|0||57|||103|
||In total 7legacies|were received during 2022/23, ofwhich
1 was a residuary|||||||sum received re|prior|years||||
||(2021/22: 6).||||||||||||||
|2.3|Total donations|and|legacies|||2734=.=|.|.:3|'
—.0||2,737|||2,349|
||||||||||||Total|||Total|
|||||||Unrestricted|.Restricted||Endowment||2023|||2022|
|2.4|Grants|||||Funds
f000,.||Funds
OOOO|. Funds
OOOO||Funds
f000|||Funds
f000|
||Grants from Charities||||||||||||||
||Red Sky Foundation|||||0||0|0||0|||70|
||CHSA - Covid19|Healthcare|||Support Appeal|60||0|0||60|||0|
||||||||||0||60|||70|
##
##
|||NOTES TO THE|FINANCIAL STATEh|llENTS (CON|TINUED)|||
|---|---|---|---|---|---|---|---|
|Income from|3|||||Total|Total|
|charitable|||Unrestricted|Restricted|Endowment|2023|2022|
|activities|||Funds|Funds|Funds|Funds|Funds|
||||f000|OOOO|f000|OOOO|f000|
|||Course and conference fees|80|0|0|80|92|
|||8 different course types were held (2021/22: 8).||||||
|Income from|4|||||Total|Total|
|other trading|||Unrestricted|Restricted|Endowment|2023|2022|
|activities|||Funds|Funds|Funds|Funds|Funds|
||||OOOO|OOOO|f000|f000|OOOO|
|||Staff lottery||0|0|5||
||||5|0|0,|||
##
##
||||||||||||||Total||Total|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|||||||Unrestricted||Restricted||Endowment|||2023||2022|
|||||||Funds||Funds||Funds||Funds||Funds||
|||||||EOOO||EOOO|||EOOO||E000||EOOO|
||Bought-in services from
Investment
Broker fee
Corporate
Fundraising||NHS
non'. pay|||(2)
(23)
(c1)'. .
;(26)"||0
0
(1)
0
. o
o
'(1),0||||.
.|(2)
(35)
(24)
(20)
.(1.).
'(4)
(27)::(59)'|||
||All traded investment
business|||covering|all funds is handled||by|the Charity's|investment||broker,|Rathbone
Investment||||
||Management|Ltd.||||||||||||||
||Bought-in services relate to salary recharges|||||from STSFTin|respect ofmanaging|||the staff lottery E2k|||(0.09wte-|whole tim||
||equivalent),|(2021/22:|E33kcorporate||charity|fundraiser
post 0.75wte —leaver end December||||||2021).||||
||||||||||||||Total||Total|
|||||||Unrestricted||Restricted||Endowment|||2023||2022|
|||||||Funds||Funds||Funds.||Funds||Funds||
|6.1|Cost ofCharitable
Activities|||||EOOO||EOOO|||EOOO||EOOO||EOOO|
||Patients' welfare and amenities|||||(293)||0|||0||(293)||(238)|
||Course and|conference|costs|||(56)||0|||0||(56)||(65)|
||Contributions|to NHS||||(506)||(11)|||0||(517)||(646)|
||Staff welfare|and amenities||||(137)||0|||0||(137)||(176)|
||Support and|governance|costs|||:(6'4)
(1;056)||(2)
(13)',
Governance|||0
(66)
0;;(1;069)|||.'(68)
(1;1,93)||
|6.2||||Staff / Patient||Course and'|||||||Total||Total|
|||||Welfare|and|Conference|||||||2023||2022|
|||||Amenmes||Costs||Costs||Research||Funds||Funds||
||Support and|governance|cosh|.
E000||EOOO||E000|||EOOO||f000||EOOO|
||Unrestricted||||(44)|(6)||(14)|||0||(64)||(67)|
||Restricted||||-2
(46)|0
0
(6':(1'4)„-||||.|0
:0:|"|(2)
(1
(66)',,(68)|||
##
|Analysis of|7|||||Investment|Costs of||||
|---|---|---|---|---|---|---|---|---|---|---|
|total|||||Costs of|Management|Charitable|Governance|Total|Total|
|expenditure|||||Fundraising|Costs|Activities|Costs|2023|2022|
||||||f000|f000|f000|OOOO|OOOO|f000|
|||Other|||(1)|0|(844)|0|(845)|(SO0)|
|||Bought-in services from NHS|||(2)|0|(211)|'(4)|(217)|(311)|
|||Investment
Broker fee|||0|(24)|0|0|(24)|(20)|
|||Audit|fees - Internal|audit|0|0|0|0|0|(4)|
||||provision||||||||
|||Audit|fees - external|statutory||||(10)|(10)|(17)|
||||audit provision||||||||
||||||(3)|(24)|(1,055)|(14)|(1,096)|(1,252)|
##
##
|Traded Non Current Asset|Investments:|Investments:|Investments:||||
|---|---|---|---|---|---|---|
||||||2023|2022|
||||||Total|Total|
||||||OOOO|OOOO|
|Managed
Portfolios|||||||
|Market value at 1 April|||||2,729|2,570|
|Less: Dlsposals atSales Proceeds|||values||(312)|(219)|
|Add: Acquisitions
at cost|||||1,204|209|
|Net unrealised
and realised|gain|/ (loss) on sale||and revaluation|(140)|169|
|Market value at31 March|||||3j481|. 2,729|
|Fixed Interest Fund Holding|||||||
|Market value at 1 April|||||1,061|1,143|
|Less: Dlsposals atSales Proceeds values
Add: Acquisitions
atcost
Net unrealised
and realised gain / (loss) on sale
Market value at 31 March||||and revaluation|(962)
0
(99
)
.
0,|0
0
82
(
)
1,061|
|Total non current asset Investments|||||3,481|3,790|
|Historic costat 3$ March - Managed|||Portfolios||3,896|4,221|
|(and Fixed Interest Holding year||ending 31 March 2022 only)|||||
|Traded Non Current Asset|Investments:||||31 March|31 March|
||||||2023|2022|
||||||Total|Total|
||||||ROOO|fooo|
|vestinents
iste'd:.on;a'I" 'o'riised:St'ock'Exch||||e:-|||
|In the UK|||||1,487|2,045|
|Outside the UK|||||551|183|
|Unlisted securities:|||||||
|In the UK|||||983|1,050|
|Outside the UK|||||. 460|512|
|Total|||||3,'481'|-3;790',|
|Total gross income:|||||2023|2022|
||||||Total|Total|
||||||f000|oooo|
|I
'vestmen s listed on'a:reco|ri|e'd-Stock Exch||n"e:|||
|In the UK|||||60|62|
|Outside the UK|||||5|0|
|Unlisted securities:|||||||
|In the UK|||||17|11|
|Outside the UK|||||8|8|
|Investments
in a Common
Deposit Fund|||||15|0|
|Current account / short term|Interest||||68|0|
|Total|||||1.73|,81|
##
##
||||NO|TES TO THE FINANCIAL S|TES TO THE FINANCIAL S|TATEMENTS (C|ONTINUED)||
|---|---|---|---|---|---|---|---|---|
|Analysis of|10|Amounts|falling|due within one year.|||31March|31 March|
|Trade and other|||||||2023|2022|
|Receivables|||||||KOOO|OOOO|
|||Trade|receivables||||32.|9|
|||.Amounts
due from STSFT|||||0|1|
|||Prepayments||and accrued hcome|||12|25|
|||Total receivables
falling due within one year||||||35|
|Analysis of|11
'|Cash and|cash|equivalents|||31March|31 March|
|Cash and Cash|||||||2023|2022|
|Equivalents|||||||OOOO|f000|
|||Cash|at GBS(and commercial||bank 31 March 2022)||6,424|4,849|
|||Notice|Deposits (less than 3months)||||465|463|
|||Cash|held in|dealing account with Investment||Broker|146|61|
|||Total cash and||cash equivalents|||7,035|5,373|
|Analysis of|12|Amounts|falling|due within one year.|||31March|31 March|
|Trade and other|||||||2023|2022|
|Payables|||||||f000|FOOO|
|||Amounts
due to STSFT|||||(104)|(583)|
|||Trade payables
Accruals and deferred
income|||||(45)
' l36'|(49)
(i]1|
|||Total payables||falling due within|one year||l 285)
'|'(643)|
##
##
##
##
|Analysis of|13(Continued)|13(Continued)||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Funds||||||||||||||||
|Details of|13.3|Restricted Funds||||Balance||||||||Balance||
|material||||||1 April||||||Gain on|(Loss)on|31|March|
|funds-||||||2022|Income|Expenditure|Transfers|||Disposals|Revaluation||2023|
|Restrlcted||||||f000|. f000|f000|||f000|f000|f000||fOOO|
|Funds||Material funds||||||||||||||
|||Leukaemia
Research|Legacy|||107|5|(2)|||0|1|(4)||107|
|||Ortho paedlcs bequest||||36|0|0|||0|0|(1)||35|
|||Neonatal
Unit Legacy||||13|1|(12)|||0|0|0||2|
|||Other designated
funds
Total||||21
'17,7,|2
'-:8|0
'(-14).||.|0
.'0:|0|(,1')
'(6)'|'|22
166|
||13.4|Description offunds||||||||||||||
|||Leukaemia
Research|Legacy||||For leukaemia|and lymphoma|research.|||||||
|||Orthopaedics
bequest|||||Forthe provision ofan operating|||theatre||bed spedlically||||
||||||||designed for|people suffering|from||curvature ofthe spine|||||
|||Neonatal
Unit legacy|||||For South Tyneside neonahs|||||||||
|Details of|13.5|Unrestricted
Furids||||||||||||||
|material||||||Balance||||||||Balance||
|.funds-||||||1 April||||||(Loss) on|(Loss) on|31 March||
|Unrestricted||||||2022|Income|Expenditure|Transfers|||Disposals|Revaluation||2823|
|Funds||||||f000|f000|f000||f000||f000|f000||fOOO|
|||Material funds||||||||||||||
|||Medical Equipment|purposes|||3333|2,320|(323)|||0|(45)|(65)||5,220|
|||General Purposes||||317|266|(128)|||0|(4)|(6)||445|
|||Paediatrlc department||||338|7|(4)|||0|(4)|(6)||331|
|||NeoNatal
Unit||||324|16|(10)|||0|(3)|(5)||322|
|||COVID 19||||339|66|(184)|||0|(4)|(6)||211|
|||Rise Above Cancer||||170|29|(20)|||0|(2)|(3)||174|
|||SRH ICCU||||158|58|(50)|||0|(3)|(3)||160|
|||Phoenix Unit - Chemotherapy||||131|21|(2)|||0|(2)|(3)||145|
|||Glaucoma
purposes||||147|4|(3)|||0|(2)|(3)||143|
|||Maternity
Unit||||140|3|(2)|||0|(2)|(2)||137|
|||Renal purposes||||88|14|(1)|||0|(1)|(2)||98|
|||Diabetes purposes|Legacy|||90|2|(1)|||0|(1)|(2)||88|
|||Pharmacy
department||||81|7|(1)|||0|(1)|(1)||85|
|||ALS course - Resusc||||62|37|-16|||0|(1)|(2)||80|
|||SEIGeneral Purposes||||57|22|(1)|||3|0|(1)||80|
|||Clinical Haematology||||119|2|(40)|||0|(1)|(2)||78|
|||Staff Lottery||||64|11|(7)|||0|(1)|(1)||66|
|||SRH Ward D46 Stroke (prev ESB,D41)||||87|6|(25)|||0|(1)|(1)||66|
|||STDH Cardiology
bequests||||66|2|(1)|||0|(1)|(1)||65|
|||ENT/SALT purposes||||82||(1)|||0|(1)|(1)||60|
|||Orthopaedic
Department||||73|2|(13)|||0|(1)|(1)||60|
|||SRH Cardiology||||58|3|(1)|||0|(1)|(1)||58|
|||South Tyneslde
Community||Planned|Car|85|10|(16)|||0|(1)|(1)||57|
|||Thoradc Medidne||||52|2|0|||0|(1)|(1)||52|
|||Gynaecology
purposes||||52|1|0|||0|(1)|(1)||51|
|||Other
Total Unrestricted|Funds|||1746
8,219|132
'3;044|(232)'
0
(20),
'1';082):3.';(105';|||||8
..( .)
'(129|1618
'9;950||
##
##
##
##
##